| Mitapivat versus Placebo for Pyruvate Kinase Deficiency.N Engl J Med | PMID 35417638无 PMCID | 2022-Apr-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.Blood Adv | PMID 34507355PMC9006286 | 2022-Apr-12 | 0.45 | The record is from a randomized Phase III trial in oncology (MPNs) with a drug intervention, but the abstract reports no time-to-event efficacy endpoint (OS, PFS, DFS, etc.), Kaplan-Meier analysis, or hazard ratio. The primary aim and results are about molecular and clinicohematologic responses, not the required efficacy endpoint for inclusion. | 待处理 |
| Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.Blood Adv | PMID 35130342PMC9006281 | 2022-Apr-12 | 0.90 | This is a subgroup/biomarker analysis of the ADMIRAL Phase III trial, reporting outcomes by molecular profile. While the underlying trial is Phase III, oncology, human, randomized (implied but not explicit), with a drug intervention and time-to-event endpoint, this specific report is not the primary or secondary formal result report of the trial's efficacy. It does not meet the 'original_result' criterion for inclusion as a Kaplan-Meier digitization source. | 待处理 |
| Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.Rheumatology (Oxford) | PMID 34142111PMC8996790 | 2022-Apr-11 | 0.95 | The study is a randomized, double-blind, Phase III trial in rheumatoid arthritis (non-oncology) evaluating a biosimilar adalimumab (CT-P17) versus reference adalimumab. While it meets criteria for being randomized, Phase III, human, with drug intervention, and reporting original results, it is not an oncology study. Furthermore, the primary efficacy endpoints are ACR response rates and joint damage progression, not time-to-event endpoints such as OS, PFS, DFS, etc. Therefore, it is excluded based on the non-oncology condition and lack of a time-to-event endpoint. | 待处理 |
| Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies.J Natl Compr Canc Netw | PMID 35405661无 PMCID | 2022-Apr-11 | 0.95 | The study is a randomized phase III oncology trial, but it evaluates a non-drug supportive psychotherapy intervention for coping, not a drug. The primary endpoint is adaptive coping (a psychosocial outcome), and no time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR analysis is reported or implied. | 待处理 |
| Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.J Clin Oncol | PMID 35084987无 PMCID | 2022-Apr-10 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.N Engl J Med | PMID 35388666无 PMCID | 2022-Apr-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).BMJ Open | PMID 35387813PMC8987237 | 2022-Apr-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.BMC Cancer | PMID 35366831PMC8976276 | 2022-Apr-02 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.Lancet | PMID 35367003PMC8970574 | 2022-Apr-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial.Dis Colon Rectum | PMID 34261858无 PMCID | 2022-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Age- and Time-Varying Associations Between Subjective Health and Episodic Memory in Older Adults.J Gerontol B Psychol Sci Soc Sci | PMID 34329436PMC8974348 | 2022-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.J Clin Oncol | PMID 34990281无 PMCID | 2022-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period.AIDS | PMID 35025817无 PMCID | 2022-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 35142815PMC8832307 | 2022-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 35175316PMC8855317 | 2022-Apr-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 35201290PMC8874872 | 2022-Apr-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis.Drug Alcohol Depend | PMID 35228081无 PMCID | 2022-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial.JAMA Ophthalmol | PMID 35238902PMC8895317 | 2022-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD.Drug Alcohol Depend | PMID 35286849PMC9750500 | 2022-Apr-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AVOID; a phase III, randomised controlled trial using indocyanine green for the prevention of anastomotic leakage in colorectal surgery.BMJ Open | PMID 35365509PMC8977759 | 2022-Apr-01 | 0.95 | The record is a protocol for a Phase III randomized controlled trial (AVOID) assessing indocyanine green (ICG) guidance for anastomotic leakage prevention in colorectal surgery. While it is oncology-related (colorectal surgery) and Phase III, it fails key eligibility criteria: 1) Indocyanine green is a diagnostic/imaging agent, not a therapeutic drug intervention; 2) The primary endpoint is anastomotic leakage (a complication), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.; 3) It is a protocol without reported results, not an original result report. | 待处理 |
| Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation.Clin Gastroenterol Hepatol | PMID 33965574无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.Gut | PMID 33980610PMC8921574 | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.Ann Rheum Dis | PMID 34344706PMC8921576 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.Br J Dermatol | PMID 34358343PMC9298048 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.Mult Scler | PMID 34378456无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.Mult Scler | PMID 34465252PMC8978463 | 2022-Apr | 0.90 | The study is a long-term extension of Phase III trials for multiple sclerosis (not oncology), and the primary endpoints are annualized relapse rate and disability worsening, not time-to-event outcomes like OS or PFS. | 待处理 |
| Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD).J Allergy Clin Immunol | PMID 34606832无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.Br J Dermatol | PMID 34687214PMC9303624 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.Ophthalmology | PMID 34688699无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.Ophthalmology | PMID 34767866无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.Pain Manag | PMID 34786956无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.J Diabetes Investig | PMID 34797962PMC9017614 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality of life among patients with 4 to 10 brain metastases after treatment with whole-brain radiotherapy vs. stereotactic radiotherapy: a phase III, randomized, Dutch multicenter trial.Ann Palliat Med | PMID 34806396无 PMCID | 2022-Apr | 0.95 | The study is a randomized phase III trial in oncology (brain metastases) reporting original results on a secondary quality-of-life endpoint. It is excluded because it does not involve a drug-containing intervention (both arms are radiotherapy techniques) and its primary/secondary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS, DFS, etc.) but rather patient-reported quality of life measures. | 待处理 |
| Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.J Eur Acad Dermatol Venereol | PMID 34812561PMC9299771 | 2022-Apr | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial.Ann Surg Oncol | PMID 34812982无 PMCID | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The use of topical anaesthetic in the banding of internal haemorrhoids: a feasibility study for a randomised control trial.Ann R Coll Surg Engl | PMID 34822251PMC10750542 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Moderate and Severe Persistent Hyperglycemia on Outcomes in Patients With Intracerebral Hemorrhage.Stroke | PMID 34844422无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol | PMID 34902530无 PMCID | 2022-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial.Ophthalmol Retina | PMID 34922038无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.J Thorac Oncol | PMID 34923163无 PMCID | 2022-Apr | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.Lancet Infect Dis | PMID 34942090PMC8942857 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.J Infect | PMID 34963639无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.Invest New Drugs | PMID 35031896无 PMCID | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study.Am Heart J | PMID 35045327无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Where you live matters: Township neighborhood factors important to resilience among south African children from birth to 5 years of age.Prev Med | PMID 35065975PMC11495511 | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.Ann Oncol | PMID 35093516无 PMCID | 2022-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.Gynecol Oncol | PMID 35115180无 PMCID | 2022-Apr | 0.95 | The record describes a pre-planned subgroup analysis (by age) of the primary Phase III SOLO2 trial. While it reports on efficacy (PFS, OS) and safety, it is a secondary analysis focused on a specific population, not the original primary or final report of the overall trial results. | 待处理 |
| Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.Cardiovasc Intervent Radiol | PMID 35119481PMC8940827 | 2022-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.Lancet Gastroenterol Hepatol | PMID 35120656无 PMCID | 2022-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |